FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023342413> ?p ?o ?g. }

• W2023342413 endingPage "161" @default.
• W2023342413 startingPage "156" @default.
• W2023342413 abstract "At the time of upfront treatment failure, over half of the patients with advanced pancreatic cancer are candidates for further treatment.Patients with metastatic gemcitabine-resistant pancreatic cancer were treated with mitomycin 8 mg/m(2) on day 1, ifosfamide 2,500 mg/m(2) and mesna 3,000 mg/m(2) on days 1-3 every 28 days until progressive disease. A positive responder was defined as a patient who was progression free at 6 months from trial enrollment. According to the Fleming design, a sample size of 34 patients was estimated assuming p0 = 0.05 and p1 = 0.20.Between May 2006 and December 2007, 21 patients (median age 56 years; median Karnofsky performance score 80) were enrolled. One patient died before receiving any treatment. Eighteen patients interrupted chemotherapy due to progressive disease (n = 15), toxicity (n = 2) or refusal (n = 1). Grade >2 toxicity consisted of neutropenia in 80% of patients, thrombocytopenia and fatigue in 20% and anemia in 10%. Only 1 patient was progression free at 6 months (5%). One patient had a partial response (5%) and 2 patients had stable disease (10%). Median survival was 3.7 months.Based on the poor outcome observed and on the high level of grade 3-4 toxicity, the trial was prematurely stopped and the mitomycin and ifosfamide regimen was considered insufficiently active in gemcitabine-pretreated advanced pancreatic cancer." @default.
• W2023342413 created "2016-06-24" @default.
• W2023342413 creator A5004680827 @default.
• W2023342413 creator A5013912654 @default.
• W2023342413 creator A5015245808 @default.
• W2023342413 creator A5029031145 @default.
• W2023342413 creator A5037045248 @default.
• W2023342413 creator A5038760660 @default.
• W2023342413 creator A5044079505 @default.
• W2023342413 creator A5077999346 @default.
• W2023342413 creator A5083612184 @default.
• W2023342413 date "2011-01-01" @default.
• W2023342413 modified "2023-09-23" @default.
• W2023342413 title "Salvage Therapy with Mitomycin and Ifosfamide in Patients with Gemcitabine-Resistant Metastatic Pancreatic Cancer: A Phase II Trial" @default.
• W2023342413 cites W1931508686 @default.
• W2023342413 cites W1971150016 @default.
• W2023342413 cites W1975723100 @default.
• W2023342413 cites W1978502285 @default.
• W2023342413 cites W1984254136 @default.
• W2023342413 cites W1987329654 @default.
• W2023342413 cites W1989084858 @default.
• W2023342413 cites W1989245824 @default.
• W2023342413 cites W1990161374 @default.
• W2023342413 cites W1992435888 @default.
• W2023342413 cites W2000978440 @default.
• W2023342413 cites W2009279496 @default.
• W2023342413 cites W2009325232 @default.
• W2023342413 cites W2023983707 @default.
• W2023342413 cites W2029813189 @default.
• W2023342413 cites W2043710084 @default.
• W2023342413 cites W2049529518 @default.
• W2023342413 cites W2052474764 @default.
• W2023342413 cites W2060774001 @default.
• W2023342413 cites W2067141748 @default.
• W2023342413 cites W2071796418 @default.
• W2023342413 cites W2073151826 @default.
• W2023342413 cites W2081924579 @default.
• W2023342413 cites W2082243630 @default.
• W2023342413 cites W2085382632 @default.
• W2023342413 cites W2090455659 @default.
• W2023342413 cites W2090884267 @default.
• W2023342413 cites W2097642908 @default.
• W2023342413 cites W2114680879 @default.
• W2023342413 cites W2117105709 @default.
• W2023342413 cites W2121120744 @default.
• W2023342413 cites W2121823666 @default.
• W2023342413 cites W2123344367 @default.
• W2023342413 cites W2139248078 @default.
• W2023342413 cites W2145579761 @default.
• W2023342413 cites W2148700329 @default.
• W2023342413 cites W2151046016 @default.
• W2023342413 cites W2256943140 @default.
• W2023342413 cites W2265767948 @default.
• W2023342413 cites W2885774601 @default.
• W2023342413 cites W297156177 @default.
• W2023342413 cites W4230270082 @default.
• W2023342413 cites W4240983648 @default.
• W2023342413 cites W1993277780 @default.
• W2023342413 doi "https://doi.org/10.1159/000324865" @default.
• W2023342413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21454973" @default.
• W2023342413 hasPublicationYear "2011" @default.
• W2023342413 type Work @default.
• W2023342413 sameAs 2023342413 @default.
• W2023342413 citedByCount "16" @default.
• W2023342413 countsByYear W20233424132012 @default.
• W2023342413 countsByYear W20233424132013 @default.
• W2023342413 countsByYear W20233424132014 @default.
• W2023342413 countsByYear W20233424132015 @default.
• W2023342413 countsByYear W20233424132017 @default.
• W2023342413 countsByYear W20233424132018 @default.
• W2023342413 countsByYear W20233424132019 @default.
• W2023342413 crossrefType "journal-article" @default.
• W2023342413 hasAuthorship W2023342413A5004680827 @default.
• W2023342413 hasAuthorship W2023342413A5013912654 @default.
• W2023342413 hasAuthorship W2023342413A5015245808 @default.
• W2023342413 hasAuthorship W2023342413A5029031145 @default.
• W2023342413 hasAuthorship W2023342413A5037045248 @default.
• W2023342413 hasAuthorship W2023342413A5038760660 @default.
• W2023342413 hasAuthorship W2023342413A5044079505 @default.
• W2023342413 hasAuthorship W2023342413A5077999346 @default.
• W2023342413 hasAuthorship W2023342413A5083612184 @default.
• W2023342413 hasConcept C121608353 @default.
• W2023342413 hasConcept C126322002 @default.
• W2023342413 hasConcept C141071460 @default.
• W2023342413 hasConcept C2776694085 @default.
• W2023342413 hasConcept C2777063308 @default.
• W2023342413 hasConcept C2777506904 @default.
• W2023342413 hasConcept C2778119113 @default.
• W2023342413 hasConcept C2778822529 @default.
• W2023342413 hasConcept C2780210213 @default.
• W2023342413 hasConcept C2780258809 @default.
• W2023342413 hasConcept C2780376820 @default.
• W2023342413 hasConcept C2781413609 @default.
• W2023342413 hasConcept C71924100 @default.
• W2023342413 hasConcept C90924648 @default.
• W2023342413 hasConceptScore W2023342413C121608353 @default.
• W2023342413 hasConceptScore W2023342413C126322002 @default.
• W2023342413 hasConceptScore W2023342413C141071460 @default.

• next